Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2% - Time to Buy?

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) was up 5.2% on Monday . The stock traded as high as $9.99 and last traded at $9.85. Approximately 720,401 shares were traded during trading, a decline of 73% from the average daily volume of 2,711,465 shares. The stock had previously closed at $9.36.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Guggenheim increased their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Cantor Fitzgerald lifted their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, November 12th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday. Finally, StockNews.com raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday, December 10th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.88.

Amicus Therapeutics Trading Up 5.8 %

The firm has a market cap of $2.96 billion, a PE ratio of -28.71 and a beta of 0.60. The company has a 50-day simple moving average of $10.52 and a 200 day simple moving average of $10.62. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Insider Activity

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $11.46, for a total value of $85,950.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $10,161,054.84. This represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders sold 30,401 shares of company stock valued at $339,363. 2.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Amicus Therapeutics during the 3rd quarter valued at approximately $107,000. Old West Investment Management LLC grew its stake in Amicus Therapeutics by 617.2% in the 3rd quarter. Old West Investment Management LLC now owns 340,441 shares of the biopharmaceutical company's stock valued at $3,636,000 after acquiring an additional 292,976 shares during the last quarter. Neo Ivy Capital Management acquired a new position in Amicus Therapeutics during the third quarter worth about $702,000. Geode Capital Management LLC lifted its stake in Amicus Therapeutics by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company's stock valued at $70,499,000 after buying an additional 80,926 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Amicus Therapeutics during the third quarter worth $405,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.